1-氯-3-(4-氯苯基)丙烷-2-酮 | 33107-83-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-氯-3-(4-氯苯基)丙烷-2-酮
• 英文名称: 1-chloro-3-(4-chlorophenyl)propan-2-one
• CAS: 33107-83-4
• 化学式: C₉H₈Cl₂O
• 分子量: 203.068
• InChiKey: ABTYPOQRRMEIMH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-氯-3-(4-氯苯基)丙烷-2-酮 在 cesium acetate 作用下， 以 乙醇 、 水 为溶剂， 反应 7.0h， 生成 2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h]quinoline-4-carboxylic acid
  参考文献：
  名称：

  Methods and Compositions for Treatment of Scleritis and Related Disorders

  摘要：

  目前的教导涉及抗炎物质领域，更具体地涉及对用于治疗巩膜炎、巩膜炎症状或与巩膜炎相关疾病有用的化合物。在一个方面，治疗巩膜炎、巩膜炎症状或巩膜炎相关疾病的方法通常包括向受试者施用公式I的化合物： 或其药用可接受的盐、水合物或酯，其中W 1 ，W 2 ，R 1 ，L，X，Y，Z和n 1 的定义如本文所述。

  公开号：

  US20080125454A1
• 作为产物：
  描述：

  对氯苯乙酸 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 1.0h， 生成 1-氯-3-(4-氯苯基)丙烷-2-酮
  参考文献：
  名称：

  2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[H]quinoline-4-carboxylic Acid (PSI-697):  Identification of a Clinical Candidate from the Quinoline Salicylic Acid Series of P-Selectin Antagonists

  摘要：

  P-selectin-PSGL-1 interaction causes rolling of leukocytes on the endothelial cell surface, which subsequently leads to firm adherence and leukocyte transmigration through the vessel wall into the surrounding tissues. P-selectin is upregulated on the surface of both platelets and endothelium in a variety of atherosclerosis-associated conditions. Consequently, inhibition of this interaction by means of a small molecule P-selectin antagonist is an attractive strategy for the treatment of atherosclerosis. High-throughput screening and subsequent analoging had led to the identification of compound 1 as the lead candidate. Herein, we report the continuation of this work and the discovery of a second-generation series, the tetrahydrobenzoquinoline salicylic acids. These compounds have improved pharmacokinetic properties, and a number of them have shown oral efficacy in mouse and rat models of atherogenesis and vascular injury. The lead 31 (PSI-697), is currently in clinical development for the treatment of atherothrombotic vascular events.

  DOI：

  10.1021/jm060631p

文献信息

• Methods and compositions for selectin inhibition
  申请人：Kaila Neelu

  公开号：US20050101568A1

  公开（公告）日：2005-05-12

  The present invention relates to the field of anti-inflammatory substances, and more particularly to novel compounds that act as antagonists of the mammalian adhesion proteins known as selectins. In some embodiments, methods for treating selectin mediated disorders are provided which include administration of compound of Formula I: wherein the constituent variables are defined herein.

  本发明涉及抗炎物质领域，更特别地涉及作为哺乳动物粘附蛋白拮抗剂的新化合物。在某些实施例中，提供了治疗选择素介导疾病的方法，包括给予式I的化合物： 其中组分变量在此处定义。
• A Simple and Efficient Method for the Preparation of α-Halogenated Ketones Using Iron(III) Chloride and Iron(III) Bromide as Halogen Sources with Phenyliodonium Diacetate as Oxidant
  作者：Shi-Zhong Tang、Wenshuang Zhao、Tao Chen、Yang Liu、Xiao-Ming Zhang、Fu-Min Zhang

  DOI：10.1002/adsc.201700833

  日期：2017.12.11

  ketones are both unique structure moieties existing in biologically natural products and valuable synthetic intermediates for the preparation of functional molecules. An efficient and scalable method for the preparation of α‐halogenated ketone using iron (III) chloride and iron (III) bromide as halogen sources with phenyliodonium diacetate as oxidant has been developed, featuring mild reaction conditions

  α-卤代酮既是生物天然产物中存在的独特结构部分，又是制备功能分子的有价值的合成中间体。已开发出一种高效且可扩展的方法，该方法以氯化铁（III）和溴化铁（III）为卤素源，并以二乙酸苯基碘铵作为氧化剂，制备α-卤代酮，具有反应条件温和，环境友好的试剂和广泛的底物范围。值得注意的是，使用这种开发的方法作为药物的关键步骤，完成了普拉格雷的三步合成，其克级收率为30％。另外，基于一些初步的控制实验，提出了涉及氯阳离子的反应机理。
• One-Step Synthesis of 1-Chloro-3-arylacetone Derivatives from Arylacetic Acids
  作者：Michael J. Zacuto、Robert F. Dunn、Margaret Figus

  DOI：10.1021/jo5016486

  日期：2014.9.19

  method utilizes the unique reactivity of an intermediate Mg–enolate dianion, which displays selectivity for the carbonyl carbon of chloromethyl carbonyl electrophiles. Decarboxylation of the intermediate occurs spontaneously during the reaction quench. The utility of the reaction products has been demonstrated through the total synthesis of the natural product cimiracemate B.

  已经开发出一种实用的一步法，以从容易获得的廉价苯乙酸衍生物制备α-氯酮。该方法利用了中间的Mg-烯酸双阴离子的独特反应性，该反应对氯甲基羰基亲电试剂的羰基碳表现出选择性。中间体的脱羧在反应淬灭过程中自发发生。反应产物的用途已通过天然产物西马西酸酯B的全合成得到证明。
• N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES
  申请人：GRIFFIOEN Gerard

  公开号：US20100197703A1

  公开（公告）日：2010-08-05

  This invention provides thiazolylpiperazine derivatives, and N-sulfonyl heterocyclic derivatives including phenyl- and benzyl-thiazolylpiperidine derivatives, and pharmaceutically acceptable salts thereof, which are useful active ingredients for administration in a method for the treatment of an α-synucleopathy such as Parkinson's disease, diffuse Lewy body disease, traumatic brain injury, amyotrophic lateral sclerosis, Niemann-Pick disease, Hallervorden-Spatz syndrome, Down syndrome, neuroaxonal dystrophy, multiple system atrophy and Alzheimer's disease. This invention also provides methods for making such derivatives, and pharmaceutical compositions including such derivatives together with pharmaceutically acceptable excipients.

  该发明提供了噻唑基哌嗪衍生物，以及包括苯基和苄基噻唑基哌啶衍生物的N-磺酰杂环衍生物，以及其药学上可接受的盐，这些是用于治疗α-突触核蛋白病的有效活性成分，如帕金森病、弥漫性小体病、创伤性脑损伤、肌萎缩侧索硬化症、尼曼-匹克病、哈勒沃登-施帕茨综合征、唐氏综合征、神经轴突萎缩、多系统萎缩和阿尔茨海默病的治疗方法。该发明还提供了制备这些衍生物的方法，以及包括这些衍生物和药学上可接受的辅料的药物组合物。
• QUINOLINONE DERIVATIVES FOR USE IN THE TREATMENT OF AN AUTOIMMUNE DISEASE AND/OR AN INFLAMMATORY DISEASE
  申请人：Wallner Karl Fredrik

  公开号：US20140018384A1

  公开（公告）日：2014-01-16

  There is provided compounds of formula I, wherein X 1 to X 4 , R 1 to R 4 , Y 1 , Y 2 and L are as defined in the description, and pharmaceutically-acceptable salts thereof, which may be useful in the treatment and/or prophylaxis of autoimmune diseases, inflammatory (e.g. chronic inflammatory) diseases and/or other diseases that may benefit from production of ROS (reactive oxygen species) by a NADPH oxidase complex.

  提供了具有式I的化合物，其中X1至X4，R1至R4，Y1，Y2和L如描述中定义，并且其药用盐，这些化合物可能在治疗和/或预防自身免疫疾病、炎症性（如慢性炎症性）疾病和/或其他可能受益于NADPH氧化酶复合物产生ROS（活性氧化物种）的疾病中有用。